The $78 Billion Question Affecting Dividend Stocks Today

Page 1 of 2

The $78 Billion Question Affecting Dividend Stocks TodayIt’s one of the biggest questions facing income investors today: What does the “fiscal cliff” mean for dividend stocks?

The term “fiscal cliff,” coined last year by Federal Reserve Chairmen Ben Bernanke, describes more than $500 billion in automatic tax hikes, including higher dividend tax rates; and $100 billion in spending cuts, as well as a debt limit increase.

(For more information about what the cuts mean for dividends taxes, you can see my latest write-up on the subject here.)

These measures would start Jan. 1, 2013, unless Congress comes to a compromise during the current lame-duck session. The Congressional Budget Office estimates that allowing the tax cuts to expire and going off the cliff would shrink theeconomy by 0.5% — or $78 billion — throwing the United States into a mild recession. It would also increase the unemployment rate to 9.1% by the end of 2013 from 7.9% today.

Whether or not Congress intervenes, investors are likely to see higher taxes on dividends and capital gains. But the good news is several factors suggest higher tax rates may not trigger the selloff in dividend stocks that some investors fear.

For starters, about half of dividend-paying stocks on the market are held in tax-sheltered accounts, which aren’t affected by higher dividend tax rates, according to brokerage firm Stifel Nicolaus. Much of the rest is held by hedge funds and institutions, which aren’t affected by the expiring tax cuts.

If history is any guide, then your high-yield holdings should weather any dividend tax increase in the long term. Historically, dividend stocks underperformed non-dividend payers for about six months after a dividend tax increase, according to Ned Davis Research Group.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!